WIC
JAZZ icon

Woodmont Investment Counsel’s Jazz Pharmaceuticals JAZZ Stock Holding History

Woodmont Investment Counsel’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100
Closed -$12K – 411
2016
Q3 		$12K Buy
+100
New +$13.5K ﹤0.01% 444
2015
Q4 		– Sell
-10
Closed -$1K – 548
2015
Q3 		$1K Hold
10
– – ﹤0.01% 528
2015
Q2 		$2K Buy
+10
New +$1.8K ﹤0.01% 509

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Woodmont Investment Counsel's JAZZ Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2016, closing a stake of 100 shares — an estimated $12K sold.

Woodmont Investment Counsel first reported a position in JAZZ in Q2 2015 and held it in 3 quarters. The position peaked at $12K in Q3 2016. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

  • Woodmont Investment Counsel reported no remaining Jazz Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Woodmont Investment Counsel sold 100 Jazz Pharmaceuticals shares in Q4 2016, an estimated $12K.
  • Woodmont Investment Counsel first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Woodmont Investment Counsel's Jazz Pharmaceuticals position peaked at $12K in Q3 2016.
  • 295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.